Transitional myeloproliferative disorder.
Eleven patients have been observed with clinical features of both polycythaemia vera and myelofibrosis. Detailed follow-up and repeated haematological and isotopic investigations, including the assessment of erythropoietic distribution by 52Fe scanning, over a 10 year period, have indicated that patients who initially present with this syndrome may remain in a steady state for several years and that this transitional syndrome does not necessarily imply an active or irreversible transformation into classical myelofibrosis. Therapy with iron, folic acid, alkylating agents, splenectomy or splenic irradiation may reduce the extramedullary component of myeloproliferation and allow occasional patients to revert to more classical polycythaemia vera. Radioactive phosphorus (32P) therapy may be inappropriate in polycythaemic patients with dominant extramedullary erythropoiesis, as this form of therapy has a preferential medullary action and may selectively encourage extramedullary myeloproliferation.
D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D002066:Busulfan / Q000627:therapeutic use; D005260:Female; D005492:Folic Acid / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000628:therapy; D010761:Phosphorus Radioisotopes / Q000009:adverse effects; D011087:Polycythemia Vera / Q000097:blood; D055728:Primary Myelofibrosis / Q000097:blood
D010761:Phosphorus Radioisotopes; D005492:Folic Acid; D007501:Iron; D002066:Busulfan